Primary Hyperthyroidism
Conditions
Keywords
Positron emission tomography-magnetic resonance imaging (PET-MR), Hyperthyroidism, Positron emission tomography-computed tomography (PET-CT)
Brief summary
A comparative prospective study to evaluate different imaging modalities (pet-ct and pet-mr) prior to surgery in parathyroid tumor patients.
Detailed description
Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. in addition to the conservative 99mTc-MIBI (methoxyisobutylisonitrile) and US, patients will also undergo 18FCH (¹⁸F-choline) PET/MRI for detecting adenomas and their location. imaging experts will decode the imaging exams. sensitivity and specificity of the exams will be examined.
Interventions
DEVICEPET-MR
Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
DEVICEPET-CT
Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
Sponsors
Assuta Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
Patients who meet the criteria accepted in the World Health Organization (WHO) analysis: * Symptomatic patients (constipation, depression, peptic ulcer, pathologic fractures, chronic fatigue, pain from a urinary tract stones etc..) or at least one of the following criteria: * Blood calcium levels above 1 more than normal * Creatinine clearance decreased in 30% from age expected * Urine Creatinine above 400 mg in 24 hours
Exclusion criteria
* Patients with hyperthyroidism secondary and tertiary (secondary to kidney disease) * Patients who are not eligible to sign an informed consent * Pregnant women * Patients with sensitivity (allergy) technetium or 18FCH
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adenomas size and location | 24 months | Location of adenomas by a report analyzing the pathological examination (PET-CT/PET-MR output). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Parathyroid hormone levels | 24 months | approval late addition level of parathyroid hormone (PTH) before and during the course of the operation after the conclusion of adenomas (Hormone levels). |
| Chronic disease duration | 24 months | time from chronic diseases indication and duration of symptoms measured in months (from the medical records). |
| Disease related medication consumption | 24 months | Disease related medication consumption measured in miligram (mg) for each medication (from medical records). |
Countries
Israel
Contacts
Primary ContactAvi Hefetz, MD
Outcome results
None listed